// App-Quantinova.ai

PO0561 : Pegunigalsidase Alfa, PEGylated α-Galactosidase-A Enzyme in Development for the Treatment of Fabry Disease, Shows a Correlation Between Renal Gb3 Inclusion Clearance and Reduction of Plasma Lyso-Gb3

Researchers

Presenter

  • Tuffaha AhmadM

Principal Investigators

  • Hughes Derralynn

  • Boyd Simeon

  • Giraldo Pilar

  • Holida MyrlD

  • Atta MohamedG

  • Goker-Alpan Ozlem

  • Nicholls KathleenM

  • Schiffmann Raphael

  • Maegawa Gustavo

  • Barisoni Laura

  • Colvin RobertB

  • Jennette J. Charles

  • Alon Sari

  • Szlaifer Mali

  • Almon Einat

  • Chertkoff Raul

Medical Centers

  • Kansas University Medical center, Kansas city, Kansas, United States

  • LSDU Institute of Immunity and Transplantation Royal Free London NHS Foundation Trust London United Kingdom

  • Department of Pediatrics Section of Genetics MIND Institute UC Davis Medical Center Sacramento California United States

  • Hospital de Dia Quiron Zaragoza Spain

  • University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

  • Department of Medicine Division of Nephrology Johns Hopkins Johns Hopkins University School of Medicine Baltimore Maryland United States

  • 6O&O Alpan LLC Fairfax VA United States

  • Nephrology Department the Royal Melbourne Hospital Melbourne Victoria Australia

  • Baylor Institute of Metabolic Diseases Baylor University Medical Center Dallas Texas United States

  • University of Florida Department of Pediatrics/Genetics & Metabolism Gainesville Florida United States

  • Duke University, Durham, North Carolina, United States

  • Massachusetts General Hospital Harvard Medical School Department of Pathology Boston Massachusetts United States

  • University of North Carolina Department of Pathology Chapel Hill North Carolina United States

  • Protalix Biotherapeutics Carmiel Northern Israel

Locations

  • United States

  • United Kingdom

  • Spain

  • Australia

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Fabry disease

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A


Study Design

  • Pharmacokinetics

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A